AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34180209 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan coated Vicryl 2/0 suture
Number of subjects: 49
Study 34180209 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 49
Study 32199095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 administered intravenously every week for 4 weeks, then 1000 mg every 2 weeks at 24 weeks and 48 weeks after randomisation)
Number of subjects: 38
Study 32199095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching intravenous administration)
Number of subjects: 38
Study 35457289 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise breaks (5 × 6 min cycling at 70% VO2 max)
Number of subjects: 18
Study 35457289 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of exercise (30 min cycling at 70% VO2 max)
Number of subjects: 18
Study 35457289 — intervention group
Group type: COMPARATOR
Intervention: Control condition (sitting)
Number of subjects: 18
Study 35457289 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise breaks
Number of subjects: 18
Study 35457289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise trials
Number of subjects: 18
Study 35457289 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prior to sitting
Number of subjects: 18
Study 32673049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed price sequence
Number of subjects: 0
Study 32673049 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized price sequence
Number of subjects: 0
Study 33007527 — intervention group
Group type: EXPERIMENTAL
Intervention: pQCT assessment at 12 months
Number of subjects: 1639
Study 33007527 — intervention group
Group type: EXPERIMENTAL
Intervention: pQCT assessment at 24 months
Number of subjects: 1639
Study 33007527 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of bone parameters between 12 and 24 months
Number of subjects: 1639
Study 33007527 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment of bone parameters for weight, length, and scan quality
Number of subjects: 1639
Study 35409619 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min structured protocol of nature contact
Number of subjects: 90
Study 35409619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 33259968 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA-augmented screws
Number of subjects: 50
Study 33259968 — intervention group
Group type: COMPARATOR
Intervention: Uncemented screws (Control)
Number of subjects: 50
Study 32203065 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg)
Number of subjects: 41
Study 32203065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 32203065 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 41
Study 35527576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive computer-based cognitive program using REHACOM software in addition to conventional physical therapy (aerobic training, resistive training, flexibility program)
Number of subjects: 40
Study 35527576 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy program for MS including aerobic training, resistive training, flexibility program and placebo cognitive sessions
Number of subjects: 40
Study 33001537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroids (ILCs)
Number of subjects: 22
Study 33001537 — intervention group
Group type: COMPARATOR
Intervention: Topical TCA 35%
Number of subjects: 22
Study 36411567 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone 2‐6 mg/d, olanzapine 5‐20 mg/d, quetiapine 400‐750 mg/d, aripiprazole 10‐30 mg/d, ziprasidone 80‐160 mg/d)
Number of subjects: 3010
Study 36411567 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotics (perphenazine 20‐60 mg/d, haloperidol 6‐20 mg/d)
Number of subjects: 3010
Study 34981693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 40
Study 34981693 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 40
Study 33279854 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg at day 1 of each cycle) and Tremelimumab (75 mg at day 1 for 4 cycles) - Arm A
Number of subjects: 20
Study 33279854 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab, Tremelimumab with Paclitaxel (80 mg/m2 at D1, D8, D15) - Arm B
Number of subjects: 20
Study 32609960 — intervention group
Group type: EXPERIMENTAL
Intervention: INP105 5 mg
Number of subjects: 40
Study 32609960 — intervention group
Group type: EXPERIMENTAL
Intervention: INP105 10 mg
Number of subjects: 40
Study 32609960 — intervention group
Group type: EXPERIMENTAL
Intervention: INP105 15 mg
Number of subjects: 40
Study 32609960 — intervention group
Group type: COMPARATOR
Intervention: OLZ IM 5 mg
Number of subjects: 40
Study 32609960 — intervention group
Group type: COMPARATOR
Intervention: OLZ IM 10 mg
Number of subjects: 40
Study 32609960 — intervention group
Group type: COMPARATOR
Intervention: OLZ ODT
Number of subjects: 40
Study 32609960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33170731 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 40
Study 33170731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32066609 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Safety Problems (PSPs)
Number of subjects: 10037
Study 32066609 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamnesis/diagnostic procedures
Number of subjects: 10037
Study 32066609 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 10037
Study 32066609 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 10037
Study 32066609 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent harm
Number of subjects: 10037
Study 32066609 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional treatment
Number of subjects: 10037
Study 32066609 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 10037
Study 35797268 — intervention group
Group type: EXPERIMENTAL
Intervention: Unity-framed messages
Number of subjects: 136
Study 35797268 — intervention group
Group type: COMPARATOR
Intervention: Dualism-framed messages
Number of subjects: 136
Study 32588228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tech Connect
Number of subjects: 20
Study 32588228 — intervention group
Group type: COMPARATOR
Intervention: Standard community-based mental health care (control)
Number of subjects: 20
Study 33533654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 68
Study 33533654 — intervention group
Group type: COMPARATOR
Intervention: Intralesional Candida antigen
Number of subjects: 68
Study 33180097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg, 3 times daily for 15 days
Number of subjects: 152
Study 33180097 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 15 days
Number of subjects: 152
Study 33180097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 152
Study 33180097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 35466645 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal Bevacizumab (IVB) alone
Number of subjects: 260
Study 35466645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB) + Focal Macular Photocoagulation (FMP)
Number of subjects: 260
Study 32116248 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Therapy (LT), a combination of cognitive training and stimulation
Number of subjects: 0
Study 32116248 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33576434 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred intervention with digital platform support for 6 months
Number of subjects: 139
Study 33576434 — intervention group
Group type: COMPARATOR
Intervention: Active control group with one follow-up phone call
Number of subjects: 139
Study 32397926 — intervention group
Group type: COMPARATOR
Intervention: eTICI 2B
Number of subjects: 2807
Study 32397926 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 3
Number of subjects: 2807
Study 32397926 — intervention group
Group type: EXPERIMENTAL
Intervention: eTICI 2C
Number of subjects: 2807
Study 35451656 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing supplemented by dental floss (TB + DF)
Number of subjects: 75
Study 35451656 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing (TB) alone
Number of subjects: 75
Study 34159432 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette with 10% 13C-labeled propylene glycol and glycerol
Number of subjects: 25
Study 34159432 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes spiked with the described e-liquid
Number of subjects: 25
Study 36451915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS)
Number of subjects: 36
Study 36451915 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 36
Study 32572483 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative-ASDAS using BASDAI total score as PGA replacement
Number of subjects: 2085
Study 32572483 — intervention group
Group type: COMPARATOR
Intervention: Original-ASDAS
Number of subjects: 2085
Study 32506275 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation
Number of subjects: 132
Study 32506275 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative meloxicam
Number of subjects: 132
Study 32506275 — intervention group
Group type: COMPARATOR
Intervention: Postoperative meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation
Number of subjects: 132
Study 32506275 — intervention group
Group type: COMPARATOR
Intervention: Postoperative meloxicam
Number of subjects: 132
Study 33068770 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation session in addition to companionship-training (Intervention group)
Number of subjects: 56
Study 33068770 — intervention group
Group type: COMPARATOR
Intervention: Companionship training only (Control group)
Number of subjects: 56
Study 33068770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 56
Study 33285743 — intervention group
Group type: COMPARATOR
Intervention: Afatinib monotherapy (20-40 mg)
Number of subjects: 178
Study 33285743 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus HAD-B1 combination therapy (0.972 g/day for 48 weeks)
Number of subjects: 178
Study 35691037 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 21
Study 35691037 — intervention group
Group type: COMPARATOR
Intervention: Minimal acupuncture (MA)
Number of subjects: 21
Study 34514815 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 10533
Study 35859388 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (YBLI)
Number of subjects: 140
Study 35859388 — intervention group
Group type: COMPARATOR
Intervention: Non-yoga group
Number of subjects: 140
Study 33336870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperglycaemic trials
Number of subjects: 1059
Study 32544356 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser (Group 1, n=22)
Number of subjects: 56
Study 32544356 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser probe placed in vestibule without radiation (Group 2, n=22)
Number of subjects: 56
Study 32544356 — intervention group
Group type: COMPARATOR
Intervention: No pre‐treatment (Group 3, n=12)
Number of subjects: 56
Study 32894760 — intervention group
Group type: EXPERIMENTAL
Intervention: GATA3 polymorphism rs3824662
Number of subjects: 2597
Study 34419030 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 115
Study 34419030 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 115
Study 32390113 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront autologous hematopoietic stem cell transplantation (ASCT) following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy
Number of subjects: 67
Study 32390113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DEL
Number of subjects: 67
Study 32390113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with GCB subtype
Number of subjects: 67
Study 34818873 — intervention group
Group type: EXPERIMENTAL
Intervention: BT200 (0.18-48 mg) subcutaneously
Number of subjects: 112
Study 34818873 — intervention group
Group type: EXPERIMENTAL
Intervention: BT200 with concomitant desmopressin
Number of subjects: 112
Study 34818873 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 112
Study 34481910 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 162
Study 34481910 — intervention group
Group type: COMPARATOR
Intervention: Teneligliptin
Number of subjects: 162
Study 32811485 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-Jaw (V-J) group
Number of subjects: 80
Study 32811485 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-Virtual (J-V) group
Number of subjects: 80
Study 32811485 — intervention group
Group type: COMPARATOR
Intervention: Virtual (V) group
Number of subjects: 80
Study 32811485 — intervention group
Group type: COMPARATOR
Intervention: Jaw (J) group
Number of subjects: 80
Study 35238750 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg pegloticase every 2 weeks (q2w)
Number of subjects: 34
Study 35238750 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg pegloticase every 4 weeks (q4w)
Number of subjects: 34
Study 35293167 — intervention group
Group type: EXPERIMENTAL
Intervention: WALANT technique
Number of subjects: 48
Study 35293167 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with tourniquet
Number of subjects: 48
Study 35293167 — intervention group
Group type: EXPERIMENTAL
Intervention: WALANT technique and CAMIR
Number of subjects: 48
Study 34613954 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten challenges (0, 10, 50, 100, 500, and 1,000 mg) during study A
Number of subjects: 37
Study 34613954 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten challenge with 5 or 10 mg gluten during study B
Number of subjects: 37
Study 32543258 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate maintenance pemetrexed therapy
Number of subjects: 105
Study 32543258 — intervention group
Group type: COMPARATOR
Intervention: Observation followed by pemetrexed at progression
Number of subjects: 105
Study 35717354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 4628
Study 35717354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study 33225965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (300 mg daily)
Number of subjects: 90
Study 33225965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34859267 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Tibia Nail (DTN) with double locking
Number of subjects: 6
Study 34859267 — intervention group
Group type: COMPARATOR
Intervention: Distal Tibia Nail (DTN) with triple locking
Number of subjects: 6
Study 33626029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 78
Study 33626029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 32552685 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 311
Study 36459380 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient navigation intervention
Number of subjects: 278
Study 32439860 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic containing Lactobacillus rhamnosus and Lactobacillus helveticus
Number of subjects: 816
Study 32439860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816
Study 32987227 — intervention group
Group type: EXPERIMENTAL
Intervention: FICare
Number of subjects: 185
Study 32987227 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 185
Study 34217236 — intervention group
Group type: EXPERIMENTAL
Intervention: RHD care at a tertiary hospital
Number of subjects: 100
Study 32469398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus lean red meat (Ex + Meat)
Number of subjects: 154
Study 32469398 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus carbohydrate control (C + Ex)
Number of subjects: 154
Study 36233636 — intervention group
Group type: EXPERIMENTAL
Intervention: Denneroll cervical traction orthotic + TENS therapy + hot packs
Number of subjects: 80
Study 36233636 — intervention group
Group type: COMPARATOR
Intervention: TENS therapy + hot packs
Number of subjects: 80
Study 34836149 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE; containing 500 mg epigallocatechin-3-gallate)
Number of subjects: 12
Study 34836149 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 35468319 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 106
Study 35468319 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 106
Study 32828213 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Trauma Centers (TCs)
Number of subjects: 0
Study 32828213 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Trauma Centers (TCs)
Number of subjects: 0
Study 32828213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Trauma Center (TC)
Number of subjects: 0
Study 32828213 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Transport Time (TT) with 3 TCs
Number of subjects: 0
Study 32828213 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Transport Time (TT) with 2 TCs
Number of subjects: 0
Study 32828213 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Transport Time (TT) with 1 TC
Number of subjects: 0
Study 36371442 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (Health Manager) for 4 weeks
Number of subjects: 33
Study 36371442 — intervention group
Group type: COMPARATOR
Intervention: Self-management education materials in a portable document format (Control)
Number of subjects: 33
Study 32507389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 241
Study 32507389 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 241
Study 33296798 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 33
Study 33296798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32891272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 24
Study 32891272 — intervention group
Group type: COMPARATOR
Intervention: No aroma (control)
Number of subjects: 24
Study 36152359 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia group (n = 28)
Number of subjects: 86
Study 36152359 — intervention group
Group type: EXPERIMENTAL
Intervention: Other mental illness group (n = 31)
Number of subjects: 86
Study 36152359 — intervention group
Group type: COMPARATOR
Intervention: No mental illness group (n = 27)
Number of subjects: 86
Study 36152359 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including schizophrenia and other mental illness)
Number of subjects: 86
Study 36152359 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 86
Study 33929612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-augmented odontoid screw (OG)
Number of subjects: 16
Study 33929612 — intervention group
Group type: COMPARATOR
Intervention: Posterior-instrumented fusion (HG)
Number of subjects: 16
Study 32402495 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsuturing (Group I)
Number of subjects: 80
Study 32402495 — intervention group
Group type: COMPARATOR
Intervention: Fibrin sealant reinforced microsuturing (Group II)
Number of subjects: 80
Study 32402495 — intervention group
Group type: EXPERIMENTAL
Intervention: Couplers (Group III)
Number of subjects: 80
Study 32402495 — intervention group
Group type: EXPERIMENTAL
Intervention: Staplers (Group IV)
Number of subjects: 80
Study 32402495 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Assisted Vascular Anastomosis (LAVA) (Group V)
Number of subjects: 80
Study 34117622 — intervention group
Group type: EXPERIMENTAL
Intervention: Early total enteral nutrition (80 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Number of subjects: 60
Study 34117622 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Number of subjects: 60
Study 34948514 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Stroop task (MF condition)
Number of subjects: 11
Study 34948514 — intervention group
Group type: COMPARATOR
Intervention: Watching a documentary (control condition)
Number of subjects: 11
Study 34550306 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition strategy (increased portions of low-energy-dense vegetables and fruits by 50%)
Number of subjects: 53
Study 34550306 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution strategy (increased portions of vegetables and fruits by 50% and reduced portions of other foods by equivalent weight)
Number of subjects: 53
Study 34550306 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition strategy
Number of subjects: 53
Study 34550306 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution strategy
Number of subjects: 53
Study 34550306 — intervention group
Group type: COMPARATOR
Intervention: Control (typical portions for all food groups)
Number of subjects: 53
Study 34526434 — intervention group
Group type: COMPARATOR
Intervention: ARC‐HBR criteria group 0 (0 major with ≤ 1 minor, N=6,792)
Number of subjects: 12093
Study 34526434 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 1 (1 major with 0 minor, N=1,705)
Number of subjects: 12093
Study 34526434 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 2 (0 major with ≥ 2 minors, N=790)
Number of subjects: 12093
Study 34526434 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC‐HBR criteria group 3 (1 major with ≥ 1 minor, N=1,709)
Number of subjects: 12093